Skip to main content
SpringerLink
Log in

Systemic Treatment Options for Medical Device-Associated Infection

  • Chapter
  • First Online:
Biomaterials Associated Infection

  • 2095 Accesses

Abstract

Difficulties in eradicating medical device-related infections are primarily related to the presence of bacterial biofilms. The foreign body can often facilitate such infections, which may be usually caused by non-aggressive microorganisms with the ability to form biofilms even at low inoculum size.

The biofilm is responsible for several phenotypic changes in the bacteria including increased minimal bactericidal concentrations (tolerance to antibiotics). Other factors that have also been related to difficulties in the treatment of medical device-related infections are functional abnormalities in the activity of phagocytic cells in contact with the foreign body and the presence of intracellular bacteria.

While the anatomical location of the medical device can determine certain aspects of the treatment of these infections, this therapy must include an appropriate and lengthy antibiotic treatment combined with adequate surgical intervention. Antimicrobial therapy needs to be carefully designed, and the antibiotics to use against device-related infections can be chosen according both to their activity against bacterial biofilms and nongrowing microorganisms, and to their intracellular efficacy.

The specific characteristics of medical device-related infections, as well as the difficulties involved in their treatment, mean that multidisciplinary medical teams are required to ensure the optimal approach to and management of this pathology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351(16):1645–54.

    Article  CAS  Google Scholar 

  2. Del Pozo JL, Patel R. Clinical practice Infection associated with prosthetic joints. N Engl J Med. 2009;361(8):787–94.

    Article  Google Scholar 

  3. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358 (9276):135–8.

    Article  CAS  Google Scholar 

  4. Chuard C, Lucet JC, Rohner P, Herrmann M, Auckenthaler R, Waldvogel FA, Lew DP. Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials. J Infect Dis. 1991;163(6):1369–73.

    Article  CAS  Google Scholar 

  5. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15(2):167–93.

    Article  CAS  Google Scholar 

  6. Zimmerli W, Lew PD, Waldvogel FA. Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. J Clin Invest. 1984;73(4):1191–200.

    Article  CAS  Google Scholar 

  7. Proctor RA, Balwit JM, Vesga O. Variant subpopulations of Staphylococcus aureus as cause of persistent and recurrent infections. Infect Agents Dis. 1994;3(6):302–12.

    CAS  Google Scholar 

  8. Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M, Peters G. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol. 2006;4(4):295–305.

    Article  CAS  Google Scholar 

  9. Boelens JJ, Dankert J, Murk JL, Weening JJ, van der Poll T, Dingemans KP, Koole L, Laman JD, Zaat SA. Biomaterial-associated persistence of Staphylococcus epidermidis in pericatheter macrophages. J Infect Dis. 2000;181(4):1337–49.

    Article  CAS  Google Scholar 

  10. Broekhuizen CA, de Boer L, Schipper K, Jones CD, Quadir S, Feldman RG, Dankert J, Vandenbroucke-Grauls CM, Weening JJ, Zaat SA. Peri-implant tissue is an important niche for Staphylococcus epidermidis in experimental biomaterial-associated infection in mice. Infect Immun. 2007;75(3):1129–36.

    Article  CAS  Google Scholar 

  11. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med. 2004;350(14):1422–9.

    Article  CAS  Google Scholar 

  12. Costerton JW. Biofilm theory can guide the treatment of device-related orthopaedic infections. Clin Orthop Relat Res. 2005;437:7–11.

    Article  Google Scholar 

  13. Widmer AF, Frei R, Rajacic Z, Zimmerli W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis. 1990;162(1):96–102.

    Article  CAS  Google Scholar 

  14. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA. 1998;279(19):1537–41.

    Article  CAS  Google Scholar 

  15. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318–22.

    Article  CAS  Google Scholar 

  16. Gilbert P, Collier PJ, Brown MR. Influence of growth rate on susceptibility to antimicrobial agents: biofilms, cell cycle, dormancy, and stringent response. Antimicrob Agents Chemother. 1990;34(10):1865–8.

    Article  CAS  Google Scholar 

  17. Anwar H, Dasgupta MK, Costerton JW. Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob Agents Chemother. 1990;34(11):2043–6.

    Article  CAS  Google Scholar 

  18. Blaser J, Vergeres P, Widmer AF, Zimmerli W. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob Agents Chemother. 1995;39(5):1134–9.

    Article  CAS  Google Scholar 

  19. Zimmerli W, Frei R, Widmer AF, Rajacic Z. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother. 1994;33(5):959–67.

    Article  CAS  Google Scholar 

  20. Farber BF, Kaplan MH, Clogston AG. Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics. J Infect Dis. 1990;161(1):37–40.

    Article  CAS  Google Scholar 

  21. Singh R, Ray P, Das A, Sharma M. Penetration of antibiotics through Staphylococcus aureus and Staphylococcus epidermidis biofilms. J Antimicrob Chemother. 2010;65(9):1955–8.

    Article  CAS  Google Scholar 

  22. Murillo O, Domenech A, Garcia A, Tubau F, Cabellos C, Gudiol F, Ariza J. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(12):4011–7.

    Article  CAS  Google Scholar 

  23. Murillo O, Pachon ME, Euba G, Verdaguer R, Carreras M, Cabellos C, Cabo J, Gudiol F, Ariza J. Intracellular antimicrobial activity appearing as a relevant factor in antibiotic efficacy against an experimental foreign-body infection caused by Staphylococcus aureus. J Antimicrob Chemother. 2009;64(5):1062–6.

    Article  CAS  Google Scholar 

  24. Ellington JK, Harris M, Hudson MC, Vishin S, Webb LX, Sherertz R. Intracellular Staphylococcus aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis. J Orthop Res. 2006;24(1):87–93.

    Article  Google Scholar 

  25. Gresham HD, Lowrance JH, Caver TE, Wilson BS, Cheung AL, Lindberg FP. Survival of Staphylococcus aureus inside neutrophils contributes to infection. J Immunol. 2000;164(7):3713–22.

    CAS  Google Scholar 

  26. Sendi P, Rohrbach M, Graber P, Frei R, Ochsner PE, Zimmerli W. Staphylococcus aureus small colony variants in prosthetic joint infection. Clin Infect Dis. 2006;43(8):961–7.

    Article  Google Scholar 

  27. Maurin M, Raoult D. Intracellular organisms. Int J Antimicrob Agents. 1997;9(1):61–70.

    Article  CAS  Google Scholar 

  28. Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother. 2006;50(3):841–51.

    Article  CAS  Google Scholar 

  29. Carryn S, Chanteux H, Seral C, Mingeot-Leclercq MP, Van Bambeke F, Tulkens PM. Intracellular pharmacodynamics of antibiotics. Infect Dis Clin North Am. 2003;17(3):615–34.

    Article  Google Scholar 

  30. Gov Y, Bitler A, Dell’Acqua G, Torres JV, Balaban N. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis. Peptides. 2001;22(10):1609–20.

    Article  CAS  Google Scholar 

  31. Balaban N, Giacometti A, Cirioni O, Gov Y, Ghiselli R, Mocchegiani F, Viticchi C, Del Prete MS, Saba V, Scalise G, Dell’Acqua G. Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. J Infect Dis. 2003;187(4):625–30.

    Article  CAS  Google Scholar 

  32. Balaban N, Goldkorn T, Gov Y, Hirshberg M, Koyfman N, Matthews HR, Nhan RT, Singh B, Uziel O. Regulation of Staphylococcus aureus pathogenesis via target of RNAIII-activating protein (TRAP). J Biol Chem. 2001;276(4):2658–67.

    CAS  Google Scholar 

  33. Balaban N, Cirioni O, Giacometti A, Ghiselli R, Braunstein JB, Silvestri C, Mocchegiani F, Saba V, Scalise G. Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP. Antimicrob Agents Chemother. 2007;51(6):2226–9.

    Article  CAS  Google Scholar 

  34. Garrigos C, Murillo O, Euba G, et al. Study of the efficacy of RNA III inhibiting peptide (RIP) alone and in combination with vancomycin in an experimental foreign-body infection by methicillin-resistan Staphylococcus aureus. 50th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010); 2010 Sep 12–15; Boston: B-710

    Google Scholar 

  35. Yasuda H, Ajiki Y, Koga T, Yokota T. Interaction between clarithromycin and biofilms formed by Staphylococcus epidermidis. Antimicrob Agents Chemother. 1994;38(1):138–41.

    Article  CAS  Google Scholar 

  36. Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob Agents Chemother. 2010;54(10):4329–34.

    Article  CAS  Google Scholar 

  37. Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections. J Bone Joint Surg Am. 1996;78(4):512–23.

    CAS  Google Scholar 

  38. Widmer AF, Gaechter A, Ochsner PE, Zimmerli W. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis. 1992;14(6):1251–3.

    Article  CAS  Google Scholar 

  39. Drancourt M, Stein A, Argenson JN, Zannier A, Curvale G, Raoult D. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother. 1993;37(6):1214–8.

    Article  CAS  Google Scholar 

  40. Bahl D, Miller DA, Leviton I, Gialanella P, Wolin MJ, Liu W, Perkins R, Miller MH. In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1997;41(6):1293–7.

    CAS  Google Scholar 

  41. Eng RH, Padberg FT, Smith SM, Tan EN, Cherubin CE. Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria. Antimicrob Agents Chemother. 1991;35(9):1824–8.

    Article  CAS  Google Scholar 

  42. Murillo O, Pachon ME, Euba G, Verdaguer R, Tubau F, Cabellos C, Cabo J, Gudiol F, Ariza J. Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection. Antimicrob Agents Chemother. 2008;52(10):3681–6.

    Article  CAS  Google Scholar 

  43. Trampuz A, Murphy CK, Rothstein DM, Widmer AF, Landmann R, Zimmerli W. Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. Antimicrob Agents Chemother. 2007;51(7):2540–5.

    Article  CAS  Google Scholar 

  44. San Juan R, Garcia-Reyne A, Caba P, Chaves F, Resines C, Llanos F, Lopez-Medrano F, Lizasoain M, Aguado JM. Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections. Antimicrob Agents Chemother. 2010;54(12):5161–6.

    Article  CAS  Google Scholar 

  45. Vindel A, Cuevas O, Cercenado E, Marcos C, Bautista V, Castellares C, Trincado P, Boquete T, Perez-Vazquez M, Marin M, Bouza E. Methicillin-resistant Staphylococcus aureus in Spain: molecular epidemiology and utility of different typing methods. J Clin Microbiol. 2009;47(6):1620–7.

    Article  CAS  Google Scholar 

  46. Baldoni D, Haschke M, Rajacic Z, Zimmerli W, Trampuz A. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob Agents Chemother. 2009;53(3):1142–8.

    Article  CAS  Google Scholar 

  47. Murillo O, Garrigos C, Pachon ME, Euba G, Verdaguer R, Cabellos C, Cabo J, Gudiol F, Ariza J. Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53(10):4252–7.

    Article  CAS  Google Scholar 

  48. Bassetti M, Di Biagio A, Cenderello G, Del Bono V, Palermo A, Cruciani M, Bassetti D. Linezolid treatment of prosthetic hip Infections due to methicillin-resistant Staphylococcus aureus (MRSA). J Infect. 2001;43(2):148–9.

    Article  CAS  Google Scholar 

  49. Bassetti M, Vitale F, Melica G, Righi E, Di Biagio A, Molfetta L, Pipino F, Cruciani M, Bassetti D. Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother. 2005;55(3):387–90.

    Article  CAS  Google Scholar 

  50. Jover-Saenz A, Gaite FB, Ribelles AG, Porcel-Perez JM, Garrido-Calvo S. Linezolid treatment of total prosthetic knee infection due to methicillin-resistant Staphylococcus epidermidis. J Infect. 2003;47(1):87–8.

    Article  Google Scholar 

  51. Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents. 2009;34(1):8.e1–9.

    Article  CAS  Google Scholar 

  52. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58(6):1221–9.

    Article  CAS  Google Scholar 

  53. Vaudaux P, Fleury B, Gjinovci A, Huggler E, Tangomo-Bento M, Lew DP. Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53(7):3150–2.

    Article  CAS  Google Scholar 

  54. Mascio CT, Alder JD, Silverman JA. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007;51(12):4255–60.

    Article  CAS  Google Scholar 

  55. John AK, Baldoni D, Haschke M, Rentsch K, Schaerli P, Zimmerli W, Trampuz A. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother. 2009;53(7) :2719–24.

    Article  CAS  Google Scholar 

  56. Garrigos C, Murillo O, Euba G, Verdaguer R, Tubau F, Cabellos C, Cabo J, Ariza J. Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54(12):5251–6.

    Article  CAS  Google Scholar 

  57. Ariza J, Euba G, Murillo O. Orthopedic device-related infections. Enferm Infecc Microbiol Clin. 2008;26(6):380–90.

    Article  Google Scholar 

  58. Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents. 2007;30(1):11–8.

    Article  CAS  Google Scholar 

  59. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333–41.

    Article  CAS  Google Scholar 

  60. Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents. 2009;34(2):111–20.

    Article  CAS  Google Scholar 

  61. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589–601.

    Article  CAS  Google Scholar 

  62. Meehan AM, Osmon DR, Duffy MC, Hanssen AD, Keating MR. Outcome of penicillin-susceptible streptococcal prosthetic joint infection treated with debridement and retention of the prosthesis. Clin Infect Dis. 2003;36(7):845–9.

    Article  CAS  Google Scholar 

  63. Euba G, Lora-Tamayo J, Murillo O, Pedrero S, Cabo J, Verdaguer R, Ariza J. Pilot study of ampicillin-ceftriaxone combination for treatment of orthopedic infections due to Enterococcus faecalis. Antimicrob Agents Chemother. 2009;53(10):4305–10.

    Article  CAS  Google Scholar 

  64. Ivert TS, Dismukes WE, Cobbs CG, Blackstone EH, Kirklin JW, Bergdahl LA. Prosthetic valve endocarditis. Circulation. 1984;69(2):223–32.

    Article  CAS  Google Scholar 

  65. Calderwood SB, Swinski LA, Waternaux CM, Karchmer AW, Buckley MJ. Risk factors for the development of prosthetic valve endocarditis. Circulation. 1985;72(1):31–7.

    Article  CAS  Google Scholar 

  66. Karchmer AW, Longworth DL. Infections of intracardiac devices. Infect Dis Clin North Am. 2002;16(2):477–505. Xii.

    Article  Google Scholar 

  67. Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler Jr VG, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falco V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Utili R, Wang A, Woods CW, Cabell CH. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009;169(5):463–73.

    Article  Google Scholar 

  68. Gandelman G, Frishman WH, Wiese C, Green-Gastwirth V, Hong S, Aronow WS, Horowitz HW. Intravascular device infections: epidemiology, diagnosis, and management. Cardiol Rev. 2007;15(1):13–23.

    Article  Google Scholar 

  69. Baddour LM, Wilson WR, Bayer AS, Fowler Jr VG, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;111(23):e394–434.

    Article  Google Scholar 

  70. Horstkotte D, Follath F, Gutschik E, Lengyel M, Oto A, Pavie A, Soler-Soler J, Thiene G, von Graevenitz A, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Fernandez Burgos E, Lekakis J, Lindahl B, Mazzotta G, Morais J, Smiseth OA, Vahanian A, Delahaye F, Parkhomenko A, Filipatos G, Aldershvile J, Vardas P. Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology. Eur Heart J. 2004;25(3):267–76.

    Article  Google Scholar 

  71. Archer GL, Johnston JL, Vazquez GJ, Haywood 3rd HB. Efficacy of antibiotic combinations including rifampin against methicillin-resistant Staphylococcus epidermidis: in vitro and in vivo studies. Rev Infect Dis. 1983;5 Suppl 3:S538–42.

    Article  CAS  Google Scholar 

  72. Kobasa WD, Kaye KL, Shapiro T, Kaye D. Therapy for experimental endocarditis due to Staphylococcus epidermidis. Rev Infect Dis. 1983;5 Suppl 3:S533–7.

    Article  CAS  Google Scholar 

  73. Fowler Jr VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–65.

    Article  CAS  Google Scholar 

  74. Marco F, de la Maria CG, Armero Y, Amat E, Soy D, Moreno A, del Rio A, Almela M, Mestres CA, Gatell JM, Jimenez de Anta MT, Miro JM. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2008;52(7):2538–43.

    Article  CAS  Google Scholar 

  75. Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47(5):1714–8.

    Article  CAS  Google Scholar 

  76. Falagas ME, Giannopoulou KP, Ntziora F, Vardakas KZ. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother. 2007;60(1):7–19.

    Article  CAS  Google Scholar 

  77. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother. 2006;58(2):273–80.

    Article  CAS  Google Scholar 

  78. Miro JM, Del Rio A, Moreno A, et al. Efficacy and safety of fosfomycin plus imipenem for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) native valve endocarditis (NVE): preliminary results of a clinical trial. 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008); 2008 Oct 25–28; Washington, DC: L-1523

    Google Scholar 

  79. Sieradzki K, Tomasz A. Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics. J Antimicrob Chemother. 1997;39(Suppl A):47–51.

    Article  CAS  Google Scholar 

  80. Baddour LM, Bettmann MA, Bolger AF, Epstein AE, Ferrieri P, Gerber MA, Gewitz MH, Jacobs AK, Levison ME, Newburger JW, Pallasch TJ, Wilson WR, Baltimore RS, Falace DA, Shulman ST, Tani LY, Taubert KA. Nonvalvular cardiovascular device-related infections. Circulation. 2003;108(16):2015–31.

    Article  Google Scholar 

  81. Bracke FA, Meijer A, van Gelder LM. Pacemaker lead complications: when is extraction appropriate and what can we learn from published data? Heart. 2001;85(3):254–9.

    Article  CAS  Google Scholar 

  82. Reilly L. Aortic graft infection: evolution in management. Cardiovasc Surg. 2002;10(4):372–7.

    Article  Google Scholar 

  83. Kudva A, Hye RJ. Management of infectious and cutaneous complications in vascular access. Semin Vasc Surg. 1997;10(3):184–90.

    CAS  Google Scholar 

  84. Yeager RA, Taylor Jr LM, Moneta GL, Edwards JM, Nicoloff AD, McConnell DB, Porter JM. Improved results with conventional management of infrarenal aortic infection. J Vasc Surg. 1999;30(1):76–83.

    Article  CAS  Google Scholar 

  85. Martinez E, Rello J, Coll P. Clinical diagnosis of ventriculostomy-related infections. Lancet. 1994;344(8928):1015–6.

    Article  CAS  Google Scholar 

  86. Yogev R, Bisno A. Infections of central nervous system shunts. In: Waldvogel F, Bisno AL, editors. Infections associated with indwelling medical devices. 3rd ed. Washington, DC: ASM Press, 2000; 231–46.

    Google Scholar 

  87. Schreffler RT, Schreffler AJ, Wittler RR. Treatment of cerebrospinal fluid shunt infections: a decision analysis. Pediatr Infect Dis J. 2002;21(7):632–6.

    Article  Google Scholar 

  88. Pittet B, Montandon D, Pittet D. Infection in breast implants. Lancet Infect Dis. 2005;5(2): 94–106.

    Google Scholar 

  89. Gabriel SE, Woods JE, O’Fallon WM, Beard CM, Kurland LT, Melton 3rd LJ. Complications leading to surgery after breast implantation. N Engl J Med. 1997;336(10):677–82.

    Article  CAS  Google Scholar 

  90. Mulcahy JJ. Surgical management of penile prosthesis complications. Int J Impot Res. 2000;12 Suppl 4:S108–11.

    Article  Google Scholar 

  91. Wilson SK, Delk 2nd JR. Inflatable penile implant infection: predisposing factors and treatment suggestions. J Urol. 1995;153(3 Pt 1):659–61.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, IDIBELL, Hospital Universitari Bellvitge, Barcelona, Spain

    Oscar Murillo, Jaime Lora-Tamayo & Javier Ariza

Authors
  1. Oscar Murillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaime Lora-Tamayo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Javier Ariza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oscar Murillo .

Editor information

Editors and Affiliations

  1. AO Research Institute Davos, Clavadelerstrasse 8, Davos Platz, 7270, Switzerland

    T. Fintan Moriarty

  2. , Medical Microbiology, Academic Medical Center, Meibergdreef 15, Amsterdam, 1105 AZ, Netherlands

    Sebastian A.J. Zaat

  3. University Medical Center Groningen, A. Deusinglaan 1, Groningen, 9713 AV, Netherlands

    Henk J. Busscher

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Murillo, O., Lora-Tamayo, J., Ariza, J. (2013). Systemic Treatment Options for Medical Device-Associated Infection. In: Moriarty, T., Zaat, S., Busscher, H. (eds) Biomaterials Associated Infection. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1031-7_9

Download citation

Publish with us

Policies and ethics

Search

Navigation